Assembly Biosciences

Assembly Biosciences is a clinical stage biotechnology company which develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The Company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions, and a patent pending delivery system, GEMICEL.

Company Growth (employees)
Type
Public
HQ
Carmel, US
Founded
2005
Size (employees)
69 (est)+36%
Assembly Biosciences was founded in 2005 and is headquartered in Carmel, US

Assembly Biosciences Office Locations

Assembly Biosciences has offices in Carmel and San Francisco
Carmel, US (HQ)
310 11711 N Meridian St
San Francisco, US
409 Illinois St
Show all (2)

Assembly Biosciences Financials and Metrics

Assembly Biosciences Financials

USD

Net income (Q2, 2017)

(13.6 m)

EBIT (Q2, 2017)

(13.6 m)

Market capitalization (23-Feb-2018)

982.8 m

Cash (30-Jun-2017)

39.5 m
Assembly Biosciences's current market capitalization is $982.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

33.1 m

General and administrative expense

12.2 m

Operating expense total

45.3 m

EBIT

(98.2 m)(24 m)(29.7 m)(45.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

1.1 m3.7 m3.8 m4.7 m4.6 m8.1 m7.5 m8.8 m10.6 m12.1 m

General and administrative expense

1.4 m7.4 m3.4 m2.5 m2.5 m3.2 m2.9 m2.8 m4 m3.8 m

Operating expense total

2.5 m11.1 m7.2 m7.2 m7.1 m11.3 m10.5 m11.7 m14.6 m15.9 m

EBIT

(2.5 m)(11.1 m)(7.2 m)(7.2 m)(7.1 m)(11.3 m)(10.5 m)(11.7 m)(13.9 m)(13.6 m)
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

81.3 k14.6 m37 m20.5 m27.1 m29.1 m27.1 m28.6 m

Inventories

611.2 k

Current Assets

27.1 m29.2 m68.4 m53.6 m

PP&E

156.4 k148.6 k214.7 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

21.3 m17.9 m96.1 m53.5 m36.4 m20.4 m20.3 m23.8 m70.8 m39.5 m

Accounts Receivable

1.1 m

Current Assets

21.7 m18.1 m96.3 m71.3 m66.5 m59.1 m64.1 m59.3 m92.2 m77.7 m

PP&E

173.2 k174 k156.5 k132.2 k113.7 k128.5 k182.8 k131.9 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(23.8 m)(28.5 m)(44.3 m)

Depreciation and Amortization

6.2 k11 k65 k80.3 k

Inventories

93.1 k

Accounts Payable

(107.4 k)(2.5 m)456.1 k1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)(27.5 m)

Accounts Payable

2.3 m1.4 m1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m
Y, 2017

Financial Leverage

2.2 x
Show all financial metrics

Assembly Biosciences Market Value History

Assembly Biosciences's Web-traffic and Trends

Assembly Biosciences Online and Social Media Presence

Assembly Biosciences Company Life and Culture

You may also be interested in